PT UBC Medical Indonesia Tbk(ID:LABS)
Rp122.00+1.00 (+0.00%)
ID:LABS
PT UBC Medical Indonesia Tbk financials statements
Rp122.00
At close:+1.00 (+0.00%)
PT UBC Medical Indonesia Tbk (LABS) Ratios
PT UBC Medical Indonesia Tbk Ratios
ID:LABS's free cash flow for Q3 2026 was Rp4.47B. For the 2026 fiscal year, ID:LABS's free cash flow was decreased by Rp-3.75B and operating cash flow was Rp8.23B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.52 | 3.02 | 1.23 | 0.99 | 0.70 |
| Quick Ratio | 1.44 | 1.66 | 0.62 | 0.40 | 0.34 |
| Cash Ratio | 0.57 | 0.81 | 0.04 | 0.01 | 0.14 |
| Solvency Ratio | 0.37 | 0.26 | 0.11 | 0.19 | 0.09 |
| Operating Cash Flow Ratio | 0.32 | -0.26 | -0.16 | -0.25 | -0.25 |
| Short-Term Operating Cash Flow Coverage | 0.89 | -0.54 | -0.68 | -0.77 | -0.69 |
| Net Current Asset Value | Rp 106.72B | Rp 94.20B | Rp -31.37M | Rp -1.59B | Rp -26.90B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.12 | 0.18 | 0.26 | 0.18 | 0.33 |
| Debt-to-Equity Ratio | 0.18 | 0.26 | 0.84 | 0.42 | 3.38 |
| Debt-to-Capital Ratio | 0.15 | 0.21 | 0.46 | 0.30 | 0.77 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.07 | 0.28 | 0.01 | 0.13 |
| Financial Leverage Ratio | 1.50 | 1.47 | 3.25 | 2.29 | 10.29 |
| Debt Service Coverage Ratio | 1.07 | 0.69 | 0.58 | 0.62 | 0.28 |
| Interest Coverage Ratio | 16.35 | 2.94 | 2.71 | 2.19 | 28.41 |
| Debt to Market Cap | 0.03 | 0.07 | 0.08 | 0.04 | 0.06 |
| Interest Debt Per Share | 4.87 | 9.87 | 11.03 | 5.44 | 7.93 |
| Net Debt to EBITDA | -0.41 | -0.30 | 2.11 | 1.28 | 1.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 33.85% | 30.89% | 34.02% | 32.45% | 40.86% |
| EBIT Margin | 9.42% | 5.64% | 6.13% | 6.52% | 2.15% |
| EBITDA Margin | 16.52% | 14.87% | 13.13% | 15.94% | 8.17% |
| Operating Profit Margin | 10.22% | 6.06% | 4.27% | 3.64% | 2.46% |
| Pretax Profit Margin | 8.79% | 3.58% | 4.56% | 4.85% | 2.06% |
| Net Profit Margin | 6.78% | 2.00% | 1.60% | 3.04% | 0.24% |
| Continuous Operations Profit Margin | 6.78% | 2.00% | 1.60% | 3.04% | 0.24% |
| Net Income Per EBT | 77.08% | 55.81% | 35.14% | 62.60% | 11.49% |
| EBT Per EBIT | 86.04% | 59.09% | 106.63% | 133.26% | 84.06% |
| Return on Assets (ROA) | 5.92% | 1.45% | 1.37% | 2.61% | 0.32% |
| Return on Equity (ROE) | 8.86% | 2.13% | 4.44% | 5.97% | 3.34% |
| Return on Capital Employed (ROCE) | 13.06% | 5.93% | 8.34% | 7.04% | 28.56% |
| Return on Invested Capital (ROIC) | 8.64% | 2.84% | 2.23% | 3.13% | 0.89% |
| Return on Tangible Assets | 6.04% | 1.49% | 1.42% | 2.61% | 0.32% |
| Earnings Yield | 1.67% | 0.56% | 0.40% | 0.52% | 0.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.34 | 5.63 | 3.37 | 5.28 | 15.32 |
| Payables Turnover | 2.90 | 3.86 | 2.34 | 1.80 | 2.40 |
| Inventory Turnover | 1.69 | 1.42 | 1.63 | 1.79 | 2.52 |
| Fixed Asset Turnover | 5.91 | 4.41 | 3.79 | 3.73 | 4.19 |
| Asset Turnover | 0.87 | 0.73 | 0.85 | 0.86 | 1.37 |
| Working Capital Turnover Ratio | 1.84 | 2.32 | 13.73 | -7.24 | 0.00 |
| Cash Conversion Cycle | 158.62 | 227.26 | 176.84 | 70.62 | 16.58 |
| Days of Sales Outstanding | 68.39 | 64.88 | 108.37 | 69.11 | 23.82 |
| Days of Inventory Outstanding | 216.13 | 257.04 | 224.16 | 204.45 | 144.83 |
| Days of Payables Outstanding | 125.91 | 94.67 | 155.70 | 202.95 | 152.07 |
| Operating Cycle | 284.52 | 321.93 | 332.53 | 273.57 | 168.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.88 | -3.46 | -3.75 | -3.81 | -5.22 |
| Free Cash Flow Per Share | 1.47 | -5.19 | -8.85 | -4.79 | -8.19 |
| Dividend Paid and CapEx Coverage Ratio | 1.61 | -2.01 | -0.74 | -3.87 | -1.76 |
| Capital Expenditure Coverage Ratio | 1.61 | -2.01 | -0.74 | -3.87 | -1.76 |
| Operating Cash Flow Coverage Ratio | 0.83 | -0.38 | -0.36 | -0.75 | -0.66 |
| Operating Cash Flow to Sales Ratio | 0.11 | -0.09 | -0.11 | -0.16 | -0.16 |
| Free Cash Flow Yield | 1.07% | -3.87% | -6.46% | -3.50% | -5.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 59.83 | 268.00 | 249.09 | 190.28 | 1756.41 |
| Price-to-Sales (P/S) Ratio | 4.06 | 3.59 | 3.96 | 5.80 | 4.16 |
| Price-to-Book (P/B) Ratio | 5.31 | 3.81 | 10.96 | 11.40 | 58.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 93.21 | -25.83 | -15.49 | -28.57 | -16.73 |
| Price-to-Operating Cash Flow Ratio | 35.35 | -38.69 | -36.50 | -35.96 | -26.23 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | -29.48 | -10.55 | 0.23 | 0.00 |
| Enterprise Value Multiple | 24.16 | 23.80 | 32.27 | 37.67 | 52.84 |
| Enterprise Value | 795.54B | 522.69B | 578.95B | 560.25B | 560.77B |
| EV to EBITDA | 24.16 | 23.80 | 32.27 | 37.67 | 52.84 |
| EV to Sales | 3.99 | 3.54 | 4.24 | 6.01 | 4.31 |
| EV to Free Cash Flow | 91.64 | -25.51 | -16.57 | -29.58 | -17.34 |
| EV to Operating Cash Flow | 34.75 | -38.21 | -39.05 | -37.23 | -27.18 |
| Tangible Book Value Per Share | 25.07 | 33.78 | 10.94 | 12.02 | 2.34 |
| Shareholders’ Equity Per Share | 25.81 | 35.13 | 12.50 | 12.02 | 2.34 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.44 | 0.65 | 0.37 | 0.89 |
| Revenue Per Share | 33.74 | 37.38 | 34.61 | 23.62 | 32.90 |
| Net Income Per Share | 2.29 | 0.75 | 0.55 | 0.72 | 0.08 |
| Tax Burden | 0.77 | 0.56 | 0.35 | 0.63 | 0.11 |
| Interest Burden | 0.93 | 0.63 | 0.74 | 0.74 | 0.96 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.23 | 0.25 | 0.29 | 0.27 | 0.30 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.69 | -4.63 | -6.77 | -5.31 | -66.93 |
Currency in IDR
